Arena and Eisai face thin sales for obesity drug Belviq

Share this article:
More reps may be needed to propel sales for Belviq
More reps may be needed to propel sales for Belviq

Despite attempts to boost the market profile of Belviq, partners Arena and Eisai appear to be facing the same woes as their prescription-obesity treatment peer Vivus: disappointing sales.

Citing IMS Health prescription data, Credit Suisse analyst Lee Kalowski wrote in September he was lowering expectations for Arena's third-quarter results by $16 million, to $3 million. He also dialed back fourth-quarter expectations from $36 million to $12 million, in addition to cutting projections through 2018.

Kalowski noted one possible reason for the sluggish performance: Eisai's field force of 200 “is close to saturating the existing prescriber base that can be serviced” by a team this size, meaning that more people may be needed to propel sales. This is in addition to the need to improve both reimbursement rates and success connecting with consumers, barriers with which Vivus, whose prescription weight-loss drug Qsymia hit the market first, continues to struggle.

Arena and Eisai have pursued a variety of strategies to market the drug, including showering employers with information that outlined the relationship between obesity and the ways it affects their costs. These touchpoints were part of an effort called Closing the Gap: Obesity Management for Employers.

Arena/Eisai delivered the consumer complement about a month later, in the form of a Believe support program for Belviq patients. Like Vivus's DTC effort, Eisai is relying on HCPs to tell patients about the consumer site, and is using sales reps and the physician website to promote the patient resource.

Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric